History of Santen

2001 - Current


Santen acquires the U.S. firm Advanced Vision Science, Inc.

Advanced Vision Science is a medical device company specializing in the research, development and manufacturing of ophthalmic medical devices. Its innovative development of intraocular lenses is expected to proffer a competitive advantage in the ophthalmology market.

Detantol Detantol, a treatment for glaucoma and ocular hypertension, 
Livostin, and anti-allergy ophthalmic solution, launched in Japan

2002Dimple Bottle

Santen Holdings U. S. Inc. established

Introduced the Dimple Bottle, newly developed for higher usability, distinguishability and productivity
Sante de U plus E alfa, Sante 40V and Sante 40 launched in Japan

2003-2005 Medium-term Management Plan (PDF: 142KB)PDF file.Page will open in a new window. devised

Noto plant received ISO14001 certification
ClariFlex foldable intraocular lenses launched in Japan

U.S. sales partnership with Johnson & Johnson Vision Care, Inc. (currently VISTAKON pharmaceuticals, LLC) started

Rescula, a treatment for glaucoma and ocular hypertension, launched in Japan
Anti-rheumatic Metlate launched in Japan
2005Santen Pharmaceutical (China) Co., Ltd. established

Takakazu Morita is appointed chairman

Akira Kurokawa is appointed president
2006-2010 Medium-term Management Plan (PDF: 535KB)PDF file.Page will open in a new window. devised
PAPILOCK Mini ophthalmic solution 0.1%, a treatment for vernal keratoconjunctivitis, launched in Japan
Sante Medical 10 and Sante AL Cool II launched in Japan
2007Suzhou Plant

Suzhou Plant established in China

Sante Uruoi Contact a launched in Japan

Completion of pharmaceutical development facility and ancillary building at Nara Research and Development Center

Santen launches Tapros, a treatment for glaucoma and ocular hypertension
Tapros is the fruit of Santen’s first global development project spanning Japan, the U.S., Europe and Asia. The product is currently being sold in Japan as well as countries in Europe and Asia, and is gaining attention in ophthalmic markets in Japan and around the world as a new type of drug that fulfills unmet needs in the glaucoma treatment domain.

Eternity foldable intraocular lens launched in Japan
Santen 40i launched in Japan
Sante Lutax, nutritional supplement launched in Japan

Santen Pharmaceutical (China) Co., Ltd. commenced marketing

Eternity Natural, a foldable intraocular lens, launched in Japan
Sante FX V Plus launched in Japan


Long-term strategic vision toward 2020 Vision 2020 created

Santen aims to be a “Specialized Pharmaceutical Company with a Global Presence” and formulated strategic steps for long-term strategic mission and steps to accomplish.

Santen Pharmaceutical Korea Co., Ltd. commenced marketing
Cosopt, a treatment of glaucoma and ocular hypertension, launched in Japan

Diquas, a treatment for dry eye syndrome, launched
Diquas Diquas is the world’s first eye drop to take advantage of the pharmacological action of a P2Y2 receptor agonist. The drug treats dry eye by promoting the secretion of water and mucin, one of the major components of tears, and returning the tear film coating in the eye back to its normal state. 


2011-2013 Medium-Term Management Plan (PDF: 297KB)PDF file.Page will open in a new window. formulated

Santen India Private Limited established
Accuject injector launched for inserting intraocular lenses
Santen acquires Novagali Pharma S.A.S. and makes it a wholly owned subsidiary

Santen Holdings EU B.V. established as a holding company

Started integrated production at the Suzhou Plant EYLEA
VEGF inhibitor EYLEA solution for intravitreal injection launched for the treatment of patients with wet age-related macular degeneration.
Pharmaceutical information is offered together with Bayer Yakuhin, Ltd.

Sante Medical Guard and Sante 40 series launched

Head Office transferred to Kita-ku, Osaka

Ho Chi Minh Representative Office established
Santen Pharmaceutical Asia Pte.Ltd. established in Singapore
TAPROS MINI, a treatment of glaucoma and ocular hypertension, launched in Japan ALESION
Alesion, a treatment of allergic conjunctivitis, launched in Japan
Eternity Natural Uni R foldable intraocular lens launched in Japan
Sante Beautéye, Sante PC, Sante Kaiteki 40 and Sante Aln launched in Japan

2014-2017 Medium-Term Management Plan (PDF: 1.59MB)PDF file.Page will open in a new window. formulated

Took over ophthalmology assets from U.S.-based Merck & Co., Inc.
Established subsidiaries in Switzerland, Italy, the U.K., Spain, Thailand, Malaysia and the Philippines
ALESION Launch of TAPCOM (tafluprost/timolol maleate), a treatment for glaucoma and ocular hypertension
Launch of Soft Santear Hitomi Stretch

Santen Leadership Competencies introduced

Santen established Santen Leadership Competencies (SLC), a framework that conveys our expectations for personnel based on Santen’s Values, along with a new personnel system based on SLC

Assigned anti-rheumatic pharmaceuticals business to AYUMI Pharmaceutical Corporation
Launch of COSOPT Mini, a treatment for glaucoma and ocular hypertension
Launch of Ikervis, a treatment for severe keratitis in adult patients with dry eye disease
Launch of New Sante de U α
Launch of nutritional supplement Sante Lutax 20 + Vitamin & Mineral
“IT General Award” received at the 2015 (33rd) Information Technology Award from the Japan Institute of Information Technology

Established Santen Business Services Co., Ltd.

Established Santen Eye Care Co., Ltd.
Acquired InnFocus
Established Chongqing Santen Kerui Pharmaceutical Co., Ltd.
Launch of Sante Medical 12, Sante Medical Guard EX and Sante Medical Active
“IR Special Award” received for its investor relations activities from the Japan Investor Relations Association


Eternity Natural Uni R foldable intraocular lens launched in Japan
Sante Beautéye contact launched in Japan
Santen Selected as a Member of Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment
Santen begins participation in UN Global Compact

Akira Kurokawa is appointed chairman

Shigeo Taniuchi is appointed president
Medium-term Management Plan (MTP2020) (PDF: 1.51MB)PDF file.Page will open in a new window. formulated
Entered into Drug Discovery and Development Agreement with PeptiDream
EYBELIS, Glaucoma and Ocular Hypertension Treatment launched in Japan
Sante Beautéye Mooncare launched in Japan
Santen Awarded for “Corporate Governance of the year 2017” by the Japan Association of Corporate Directors

Santen Canada Inc. in Canada established

Entered into Collaboration and Distribution Agreement with Glaukos for Exclusive Distribution of the MicroShunt (DE-128) in the United States
Entered into R&D collaboration and Option & Licence Agreement with Oxford Biomedica for development of gene therapy vectors for inherited retinal disease
Entered into joint sales contact with Mitsubishi Tanabe Pharma concerning Alesion and Alesion LX
Alesion LX Ophthalmic Solution 0.1%, anti-allergenic ophthalmic solution launched in Japan.
LENTIS Comfort, Low-Add Segmental Intraocular Lens for Cataract Treatment launched in Japan
Sante Medical Antibacterial and Sante PC Contact launched in Japan

Announced (Formulation of) New Long-term Vision (PDF: 574KB)PDF file.Page will open in a new window.

Aiming to Resolve Social Issues Related to the Eye Health of People around the World
Santen China Investment Co., Ltd. established
Entered into Partnership Agreement with International Telecommunication Union (ITU) Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology
Announced Establishment of Joint Venture with Verily to Develop and Commercialize Unique Ophthalmic Devices
Entered into an Exclusive Licensing Contract with jCyte in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa
Entered into a Strategic Alliance with Plano to Tackle the Global Burden of Myopia
Entered into an Exclusive License Agreement with RVL Pharmaceuticals, Inc., an Osmotica Company, in Japan, Asia, and EMEA for RVL-1201, Treatment for Acquired Blepharoptosisbr Entered into Share Purchase Agreement with U.S. Ophthalmic Company Eyevance
Entered into Long-term Partnership with Orbis International to Tackle the Increasing Burden of Eye Diseases
Entered into 10-year partnership agreement with JBFA and IBF Foundation for an Inclusive Society
Entered into Exclusive License Agreement with Aerie for Rhopressa and Rocklatan in Japan and Several Other Asian Countries
Introduced Eco-Friendly Biomass Plastic Eyedrop Bottles
LENTIS Comfort Toric launched in Japan
Hyalein®S launched in Japan

Medium-Term Plan “MTP2025” (PDF: 3.79MB)PDF file.Page will open in a new window. formulated

Established “Santen Vision for the Earth 2050”
Joined the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities
Joined the “30% Club Japan,” Taking Action to Increase Gender Diversity at Board and Senior Management
Signed the “UN Women’s Empowerment Principles” Promoting Gender Equality and Women’s Empowerment in the Workplace, Marketplace and Community
Endorsed by the Science Based Targets (SBT) initiative of Santen's CO2 emission reduction targets
Took action with IAPB to implement the first ever UN General Assembly resolution recognizing the link between eye health and sustainable development
Entered into a New Collaboration with Glaukos in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand
Entered into an exclusive licensing agreement with Sydnexis for SYD-101, a novel investigational treatment for progressive childhood myopia
Entered into Partnership with Airdoc Improve Diagnostic Rate of Fundus Ocular Diseases with AI device in China
Announced a Strategic Partnership with Singapore National Eye Centre to Develop and Deploy Internationally an Innovative Educational Programme for Development of the Eye Care Ecosystem in Asia
Entered into a joint development agreement with ActualEyes on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy
Accelerated global deployment of Rhopressa/Rhokiinsa and Rocklatan/Roclanda with Aerie Expanding the area of exclusive licensing, including Europe and China
Sante FX AL and Sante FX CL launched in Japan
Eye drop type eye wash: Well-Wash EYE launched in Japan
2022Takeshi Ito is appointed president
Completion of Third Building on Site of Shiga Product Supply Center
DIQUAS LX Ophthalmic Solution 3% for dry-eye treatment dry-eye treatment launched in Japan
Verkazia (Cyclosporine Ophthalmic Emulsion) 0.1% launched in the US
Saniodide launched in Japan
Certified as Digital Transformation Business Operator by Ministry of Economy, Trade and Industry

Announced New Medium-Term Management Plan (FY2023-FY2025)

Sante Medical Plus series launched in Japan
Selected as "The Sustainability Yearbook Member" by S&P Global